Repaglinide, an insulin secretagog, and metformin, an insulin sensitizer, targets two different pathophysiological mechanisms underlying Type 2 diabetes, namely reduced insulin secretion and ...

the manufacturer recommends that a repaglinide-metformin combination tablet should be avoided in patients with hepatic impairment. On a similar note, because of renal clearance of metformin ...